MERCK & CO. INC. reported first-quarter revenue rose 5% to $16.3 billion, beating estimates of $15.8 billion. Strong demand for cancer drug Keytruda offset a $3.62-per-share charge from the Cidara Therapeutics acquisition. Investors are weighing Merck's ability to diversify revenue before Keytruda loses patent protection later this decade.
Merck Exceeds Q1 Sales Estimates on Keytruda Performance
Merck beat quarterly sales estimates as Keytruda revenue rose to $8 billion. The firm raised its 2026 profit forecast despite costs from recent acquisitions.
Xurve View
洞察:
Xurve View











